Cost‐effectiveness analysis of dinutuximab β for the treatment of high‐risk neuroblastoma in China
An‐Le Shen,
Jie Zhao,
Li‐Ting Yu
et al.
Abstract:BackgroundDinutuximab β can be used to treat children with high‐risk neuroblastoma (NB). Due to its high price, whether dinutuximab β is cost‐effective for the treatment of high‐risk NB remains uncertain. Therefore, assessing the cost‐effectiveness of dinutuximab β in children with high‐risk NB is of high importance.MethodsThe health utilities and economic outcomes in children with high‐risk NB were projected using a partitioned survival model. The individual patient data (IPD) of add‐on treatment with dinutux… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.